Loading company…
Geneva-based Terapet SA develops imaging products for nuclear medicine and oncology, including Qualyscan and Nuclyscan.
Founded in 2019 and headquartered in Geneva, Terapet SA develops advanced imaging technology for nuclear medicine. Its products, Qualyscan and Nuclyscan, are sold to hospitals and radiotherapy clinics, and Qualyscan is designed to improve quality control in proton therapy. In February 2023 the company raised CHF 2.3 mn in a pre-Series A round from Efficient Frontier Investing, FONGIT and Nina Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in